DE60238035D1 - Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren - Google Patents

Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren

Info

Publication number
DE60238035D1
DE60238035D1 DE60238035T DE60238035T DE60238035D1 DE 60238035 D1 DE60238035 D1 DE 60238035D1 DE 60238035 T DE60238035 T DE 60238035T DE 60238035 T DE60238035 T DE 60238035T DE 60238035 D1 DE60238035 D1 DE 60238035D1
Authority
DE
Germany
Prior art keywords
inhibitors
activation
cystine derivatives
ignition factors
ignition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238035T
Other languages
English (en)
Inventor
T Nakano
M Kitazawa
K Iwasaki
K Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE60238035D1 publication Critical patent/DE60238035D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60238035T 2001-02-02 2002-01-16 Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren Expired - Lifetime DE60238035D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001027367A JP2002226457A (ja) 2001-02-02 2001-02-02 新規シスチン誘導体及び炎症因子活性化抑制剤
PCT/JP2002/000222 WO2002062751A1 (fr) 2001-02-02 2002-01-16 Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires

Publications (1)

Publication Number Publication Date
DE60238035D1 true DE60238035D1 (de) 2010-12-02

Family

ID=18892029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238035T Expired - Lifetime DE60238035D1 (de) 2001-02-02 2002-01-16 Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren

Country Status (6)

Country Link
US (1) US6914075B2 (de)
EP (1) EP1364943B1 (de)
JP (1) JP2002226457A (de)
KR (1) KR100839008B1 (de)
DE (1) DE60238035D1 (de)
WO (1) WO2002062751A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
KR20040021589A (ko) * 2001-03-13 2004-03-10 아지노모토 가부시키가이샤 화장품 또는 피부 외용제
JP4151782B2 (ja) * 2002-10-31 2008-09-17 株式会社ミルボン 整髪料
EP2289498A1 (de) * 2003-10-15 2011-03-02 Probiodrug AG Verwendung von Inhibioten von Glutaminyl Cyclase
US20070078093A1 (en) * 2003-10-16 2007-04-05 The Administrators Of The Tulane Educational Fund Methods and compositions for treating cancer
KR20060135826A (ko) * 2004-03-31 2006-12-29 코와 가부시키가이샤 외용제
DE102004020060B3 (de) * 2004-04-20 2005-06-02 Coty B.V. Kosmetisches Verfahren zur Behandlung der Haut mit Sonnenprodukten und Sonnenprodukt-Kombination
CN101065137A (zh) * 2004-09-16 2007-10-31 加利福尼亚大学董事会 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂
EP1886681A3 (de) * 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-Hydroxyphenyl)-3H-1,2-Dithiol-3-Thion-Valproatester
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
EP1838337A4 (de) 2004-12-23 2009-10-28 Arthur M Nonomura Cytochrom-p450-enzymkomplexe und behandlungsverfahren damit
RU2007143040A (ru) * 2005-04-21 2009-05-27 Гленн А. ГОЛДШТЕЙН (US) Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
WO2006136871A1 (en) * 2005-06-21 2006-12-28 Codex V S.R.L. Use of pollen extracts to treat infections, neoplasms and to balance the immune response
MY163134A (en) * 2006-03-15 2017-08-15 Suntory Holdings Ltd Composition containing riboflavin and sesamin-class compounds
US20070224154A1 (en) * 2006-03-21 2007-09-27 Access Business Group International, Llc Methods of reducing skin irritation
US9233112B2 (en) 2006-04-13 2016-01-12 Lupin Limited Pharmaceutical compositions of cefixime
US8372455B2 (en) 2006-06-12 2013-02-12 Lvmh Recherche Cosmetic composition with anti-free radical activity
US8367085B2 (en) 2006-06-12 2013-02-05 Lvmh Recherche Cosmetic composition with anti-free radical activity
FR2902002B1 (fr) * 2006-06-12 2010-08-27 Lvmh Rech Composition cosmetique anti-radicaux libres
KR101542703B1 (ko) * 2006-10-24 2015-08-06 크렘핀, 로리에 항-재흡수 및 골 형성 식이보충제 및 이의 사용 방법
WO2008064357A2 (en) * 2006-11-22 2008-05-29 University Of Florida Research Foundation, Inc. Nanoparticles for protection of cells from oxidative stress
EP1932524A1 (de) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmazeutische Präparate zur Behandlung von Entzündungserkrankungen
JP5046756B2 (ja) * 2007-06-27 2012-10-10 富士フイルム株式会社 分散組成物及びスキンケア用化粧料並びに分散組成物の製造方法
SG179481A1 (en) * 2007-03-15 2012-04-27 Suntory Holdings Ltd Anti-fatigue agent
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US8173809B2 (en) 2008-02-07 2012-05-08 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
US8143205B2 (en) * 2008-02-21 2012-03-27 S.C. Johnson & Son, Inc. Cleaning composition having high self-adhesion and providing residual benefits
US8980813B2 (en) 2008-02-21 2015-03-17 S. C. Johnson & Son, Inc. Cleaning composition having high self-adhesion on a vertical hard surface and providing residual benefits
US9410111B2 (en) 2008-02-21 2016-08-09 S.C. Johnson & Son, Inc. Cleaning composition that provides residual benefits
US8143206B2 (en) * 2008-02-21 2012-03-27 S.C. Johnson & Son, Inc. Cleaning composition having high self-adhesion and providing residual benefits
US9481854B2 (en) 2008-02-21 2016-11-01 S. C. Johnson & Son, Inc. Cleaning composition that provides residual benefits
US8993502B2 (en) * 2008-02-21 2015-03-31 S. C. Johnson & Son, Inc. Cleaning composition having high self-adhesion to a vertical hard surface and providing residual benefits
EP2265594A2 (de) * 2008-04-16 2010-12-29 Marquette University Cystein- und cystin-bioisoester zur behandlung von schizophrenie und zur milderung von drogenentzugserscheinungen
CN103251631A (zh) * 2008-05-13 2013-08-21 根梅迪卡治疗公司 用于治疗代谢性病症的水杨酸盐(酯)缀合物
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
ITMI20081947A1 (it) * 2008-11-05 2010-05-06 Vitrupharma Srl Nuovo uso di una combinazione di resveratrolo o suo analogo ed un metabolita della cisteina
WO2010086736A2 (en) * 2009-01-30 2010-08-05 Vitrupharma S.R.L. Novel use of the combination of resveratrol with cysteine and derivatives thereof
ITMI20090110A1 (it) * 2009-01-30 2010-07-31 Vitrupharma Srl Nuovo uso di una combinazione di resveratrolo o suo uso analogo e la cisteina o suo derivato
WO2010106083A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
BRPI1013878A2 (pt) * 2009-03-16 2016-04-05 Genmedica Therapeutics Sl método para tratar distúrbios metabólicos, e, composto
US7897184B1 (en) * 2009-08-13 2011-03-01 Access Business Group International Llc Topical composition with skin lightening effect
US8192745B2 (en) * 2010-01-11 2012-06-05 Madere Shawn P Nutritional supplement to improve supplementary target protein fraction (TPF) delivery, intracellular absorption and utilization
US8808757B2 (en) * 2010-02-26 2014-08-19 Jaxsen's Llc Herbal ointment for musculoskeletal and joint-related conditions
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
KR20150064091A (ko) * 2012-10-04 2015-06-10 엑스바이오테크, 인크. 정신의학적 병태의 치료법
US9023399B2 (en) * 2012-11-16 2015-05-05 NU Technology, LLC Water-soluble anti-inflammatory cream with natural ingredients base
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
US10137097B2 (en) 2015-06-08 2018-11-27 Osaka Prefecture University Public Corporation Non-peptidic GAPDH aggregation inhibitor
US10196591B2 (en) 2015-07-10 2019-02-05 S. C. Johnson & Sons, Inc. Gel cleaning composition
US10000728B2 (en) 2015-07-17 2018-06-19 S. C. Johnson & Son, Inc. Cleaning composition with propellant
US10358625B2 (en) 2015-07-17 2019-07-23 S. C. Johnson & Son, Inc. Non-corrosive cleaning composition
WO2017034792A1 (en) 2015-08-27 2017-03-02 S. C. Johnson & Son, Inc. Cleaning gel with glycine betaine ester
US10604724B2 (en) 2015-08-27 2020-03-31 S. C. Johnson & Son, Inc. Cleaning gel with glycine betaine amide/nonionic surfactant mixture
US10836980B2 (en) 2015-12-07 2020-11-17 S. C. Johnson & Son, Inc. Acidic hard surface cleaner with glycine betaine amide
US11339353B2 (en) 2015-12-07 2022-05-24 S.C. Johnson & Son, Inc. Acidic hard surface cleaner with glycine betaine ester
CN108451970B (zh) * 2018-04-03 2021-03-02 徐州工程学院 一种提取银杏叶多糖的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2480079A (en) * 1945-08-08 1949-08-23 Upjohn Co Ring cleavage of 4-carboxythiazolidine compounds
CN100453531C (zh) 1998-10-09 2009-01-21 味之素株式会社 半胱氨酸衍生物
WO2000027378A2 (en) * 1998-11-06 2000-05-18 Roche Diagnostics Gmbh Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases

Also Published As

Publication number Publication date
US6914075B2 (en) 2005-07-05
KR100839008B1 (ko) 2008-06-19
JP2002226457A (ja) 2002-08-14
KR20030075172A (ko) 2003-09-22
EP1364943A4 (de) 2006-01-25
WO2002062751A1 (fr) 2002-08-15
EP1364943B1 (de) 2010-10-20
US20040059110A1 (en) 2004-03-25
EP1364943A1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
DE60238035D1 (de) Cystinderivate und inhibitoren zur aktivierung von entzündungsfaktoren
DE60206344D1 (de) Baueinheit von Leuchten und Zubehör
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
ATE419830T1 (de) Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60217715D1 (de) Vorrichtung zur ablation von gewebe
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60122196D1 (de) Synergistische antioxidans-kombination von delta tocols und polyphenolen
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60126838D1 (de) Amidoacetonitrile zur Bekämpfung von Endoparasiten
DE50004965D1 (de) Inhibitorkomposition zur Stabilisierung von radikalisch polymerisierbaren Substanzen
DE50010774D1 (de) Anlage zur bearbeitung von wafern
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60103889D1 (de) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidderivate zur schmerzbekämpfung
DE50013866D1 (de) Anlage zur bearbeitung von wafern
ATE281181T1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
DE10295497D2 (de) Vernetzung von Photoinitiator-initialisierten Polyacrylaten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60113533D1 (de) Derivate von beta-aminosäurenitrilen
DE50013163D1 (de) Anlage zur bearbeitung von wafern
ATE277045T1 (de) Salze von bicyclischen, n-acylierten imidazo-3- aminen und imidazo-5-aminen